EMA Authorised: Recarbrio (imipenem monohydrate;cilastatin sodium;relebactam monohydrate) — Merck Sharp & Dohme B.V.

View source ↗

Summary

EMA authorised Recarbrio (imipenem/cilastatin/relebactam) for use in Gram-negative bacterial infections, including hospital-acquired/ventilator-associated pneum…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Complicated Intra-abdominal Infection
• Complicated Urinary Tract Infection
• Hospital-acquired Bacterial Pneumonia
• Ventilator-associated Pneumonia

Drugs mentioned

• Recarbrio (imipenem/cilastatin/relebactam)

Snippet

Status: Authorised. Therapeutic area: Gram-Negative Bacterial Infections. MAH: Merck Sharp & Dohme B.V.. Decision date: 19/01/2026